Dr. Ken Macnamara has played pivotal executive roles in the biotech and biopharma industries, known for his success in driving innovation, scaling, commercialization, and high value exits.

Ken has deep experience in gene regulation, informatics/AI, gene therapy, product development, and manufacturing, at Agilent Technologies, Synpromics, and most recently as Chief Product Officer at AskBio (a Bayer company). Under his leadership, founded in data driven design, Ken’s teams have pioneered precision genetic medicines to develop patient focused therapeutics for neuromuscular, ocular, auditory, cardiovascular, metabolic, renal and the central nervous system – spanning rare and common diseases.

In January 2024, Dr. Macnamara co-founded Trogenix and serves as CEO, focused on developing transformative precision genetic medicines to address devastating diseases. Trogenix’s groundbreaking, first in-class therapeutic approach seeks to shift the health care paradigm from chronic disease management to potential curative responses. The company’s innovative Odysseus platform harnesses advances in genomics, bioinformatics, machine learning, oncology, immunology, and gene therapy to develop proprietary Synthetic Super Enhancers (SSEs) to precisely deliver therapeutic payloads to the diseased cell state.